True. The CR may be only for the sophisticated folk, which would make it even more unpopular with shareholders.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025